semaglutide immunogenicity targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis: iScience Anti-Semaglutide Antibody (M1HC), Human Chimeric

The FDA requires that the drug be safe for self-selection and self-administration by lay consumers without professional guidance, that the indication is self-diagnosable, and that the dose used in OTC setting is lower than or equivalent to the Rx dose with an adequate safety margin

Secondary progressive MS (SPMS) develops in many RRMS patients over time, characterized by gradual worsening independent of relapses

That's why absence of FDA approval here is about business case, not about lack of evidence

Most patients notice effects indirectly: sustained energy without blood sugar crashes, reduced bloating, or accelerated inch loss when combined with caloric deficit

These shifts often occur within the first 48 weeks of treatment as your body adjusts to appetite suppression and enters a caloric deficit

Your dinners might be rice with shredded chicken and a soft potato bowl